Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.14
- Piotroski Score 3.00
- Grade Buy
- Symbol (VERV)
- Company Verve Therapeutics, Inc.
- Price $4.60
- Changes Percentage (1.1%)
- Change $0.05
- Day Low $4.44
- Day High $4.69
- Year High $19.34
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/25/2025
- Fiscal Year End N/A
- Average Stock Price Target $14.00
- High Stock Price Target $30.00
- Low Stock Price Target $13.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.87
- Trailing P/E Ratio -1.82
- Forward P/E Ratio -1.82
- P/E Growth -1.82
- Net Income $-200,068,000
Income Statement
Quarterly
Annual
Latest News of VERV
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Nymex Overview: Futures Stumble as WTI Drops Below $70, Products Following -- OPIS
Oil prices dropped due to bearish sentiment after disappointment over a Chinese stimulus package. WTI fell below $68/bbl, Brent also decreased. Refined products saw smaller declines. Gasoline prices h...
By MarketWatch | 1 week ago -
Nymex Overview: Crude Futures Rise on Equity Gains; Set for Weekly Gain -- OPIS
Oil prices rose with December Nymex WTI crude up to $71.10/bbl and ICE Brent at $75.35/bbl. Both benchmarks are set to post gains. U.S. equity indexes were higher due to positive earnings reports....
By MarketWatch | 3 weeks ago -
Peter Schiff Predicts A 'Bloodbath' For MicroStrategy Stock, Calls It The Most Overvalued On MSCI World Index
Economist Peter Schiff predicts a crash for MicroStrategy Inc., calling it the most overvalued stock in the MSCI World Index. The stock's surge of 220.64% in 2024 raises concerns of a potential bloodb...
By Yahoo! Finance | 4 weeks ago
